qa_id stringlengths 27 27 | qa_group_id stringlengths 28 32 | qa_family stringclasses 3
values | subtask_type stringclasses 7
values | qa_subtype stringclasses 3
values | cluster_id stringclasses 42
values | language stringclasses 1
value | split stringclasses 1
value | question stringlengths 148 1.41k | answer stringlengths 718 10.8k | claim_ids listlengths 0 8 | paper_ids listlengths 1 5 | evidence_span_ids listlengths 0 7 | association_ids listlengths 0 4 | hypothesis_ids listlengths 0 4 | record_json stringlengths 4.37k 33.7k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
QA:7fb1c74d375a337521c18951 | QAG:31e01101edfb0eba3085175f | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Furthermore, we showed that RPTOR, PLK1, and GRB7 formed a complex, and their knockdown synergistically inhibited CRC cell proliferation with MEKi, consistent with the fact that activation of the mTOR pathway plays a pivotal role in RTKi resistance"? Return the origina... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:727032cfb7f55f8537d67e15","quotes":["Furthermore, we showed that RPTOR, PLK1, and GRB7 formed a complex, and thei... | [
"CLM:727032cfb7f55f8537d67e15",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC8732282"
] | [
"SPAN:be43030af8058f7b9bf06db3"
] | [] | [] | {"qa_id":"QA:7fb1c74d375a337521c18951","qa_group_id":"QAG:31e01101edfb0eba3085175f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Furthermore, we showed that RPTOR, PLK1, and GRB7 formed a complex... |
QA:8673ec9517db5e6e7eb51680 | QAG:f3e084de6086e14daaf069eb | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "In contrast, our results do not indicate a clear role of one of the molecular features in the etiological pathway between adiposity and colon cancer in men (adiposity was associated with all subgroups of molecular features in colon cancer)"? Return the original wording... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:77b3a83d85fc784e368adc22","quotes":["In contrast, our results do not indicate a clear role of one of the molecula... | [
"CLM:77b3a83d85fc784e368adc22",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:d2a4a9260b58378924f7229a"
] | [] | [] | {"qa_id":"QA:8673ec9517db5e6e7eb51680","qa_group_id":"QAG:f3e084de6086e14daaf069eb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"In contrast, our results do not indicate a clear role of one of th... |
QA:86a45c9049ad34bbab1b5bbf | QAG:1ba4e1ecc190e4021fcf36bb | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "The introduction of PIK3CA mutants into PIK3CA WT CRC cells promoted resistance to SMI-4a confirming that PIK3CA genotype is important for the response to SMI-4a"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:af26301e6592ce431b1b8497","quotes":["The introduction of PIK3CA mutants into PIK3CA WT CRC cells induced resistan... | [
"CLM:af26301e6592ce431b1b8497",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10461515"
] | [
"SPAN:575fc4b10ea5975e8ece663a"
] | [] | [] | {"qa_id":"QA:86a45c9049ad34bbab1b5bbf","qa_group_id":"QAG:1ba4e1ecc190e4021fcf36bb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"The introduction of PIK3CA mutants into PIK3CA WT CRC cells promot... |
QA:8800793c3d8b0845192752da | QAG:6246890f88995327746d7283 | provenance_qa | paper_evidence_availability | provenance_qa | G009 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC11991686? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiabl... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC11991686","verdict":"no_released_traceable_claim","reason":"No... | [] | [
"PMCID:PMC11991686"
] | [] | [] | [] | {"qa_id":"QA:8800793c3d8b0845192752da","qa_group_id":"QAG:6246890f88995327746d7283","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G009","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC1199168... |
QA:88ca984d24c7d238205a2a43 | QAG:6265bfe8b89a60c5575e4579 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and was associated with poor prognosis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ec7d2f34a9973035731870a6","quotes":["KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) and is ass... | [
"CLM:ec7d2f34a9973035731870a6",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC10803265"
] | [
"SPAN:35bcaa23d09cd66c4571b808"
] | [] | [] | {"qa_id":"QA:88ca984d24c7d238205a2a43","qa_group_id":"QAG:6265bfe8b89a60c5575e4579","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"KRAS G12C mutation is prevalent in ~4% of colorectal cancer (CRC) ... |
QA:88f72cda5a5007aca35a1f65 | QAG:da983693e1ebb84925fb356d | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Mutant KRAS activates β-catenin 3 , as evidenced by increased nuclear active β-catenin translocation, TOPflash activity and expression of WNT/β-catenin target genes (Cyclin D1/D2, CD44, EPHB2 and c-Myc) in 1CT-AK cells as compared with 1CT-A cells ( Fig. S5 ) . β-caten... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f0e78b997652eaab7b264210","quotes":["Mutant KRAS activates β-catenin 3 , as evidenced by increased nuclear active... | [
"CLM:f0e78b997652eaab7b264210",
"CLM:a1552d3605252a136c5cd060"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:d5824515e2136bb24e2afe6b"
] | [] | [] | {"qa_id":"QA:88f72cda5a5007aca35a1f65","qa_group_id":"QAG:da983693e1ebb84925fb356d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Mutant KRAS activates β-catenin 3 , as evidenced by increased nucl... |
QA:89e7b566a7a97ccad8e0590c | QAG:03a0c037a9e813f5107bd4ee | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Age were included as a time-varying covariate b This group excludes cases with mutations in any of the genes ( KRAS , PIK3CA , or BRAF ), as well as MMR deficient cases c This group includes cases with mutations in any of the genes ( KRAS , PIK3CA , or BRAF ) and/or ca... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ff7972d67d605716b1aece47","quotes":["Age was included as a time-varying covariate b This group excludes cases wit... | [
"CLM:ff7972d67d605716b1aece47",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:9e3d1988ea74c49f7fcc2fab"
] | [] | [] | {"qa_id":"QA:89e7b566a7a97ccad8e0590c","qa_group_id":"QAG:03a0c037a9e813f5107bd4ee","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Age were included as a time-varying covariate b This group exclude... |
QA:8a6d2d66276aa2760989a57e | QAG:f7ab18f9da63b905693b3436 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Non-occupational physical activity was not associated with overall colon cancer risk in men (Table 5 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Cl... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:efe2703a68791106d08abd79","quotes":["Non-occupational physical activity was not associated with overall colon can... | [
"CLM:efe2703a68791106d08abd79",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:234e00d3f595610a72619a1d"
] | [] | [] | {"qa_id":"QA:8a6d2d66276aa2760989a57e","qa_group_id":"QAG:f7ab18f9da63b905693b3436","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Non-occupational physical activity was not associated with overall... |
QA:8a833b41c21030d02dbe51fa | QAG:7c6bd6d24a2ab8903c810735 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "(a) DLD-1 ( PIK3CA MT) cells received the PIK3CA inhibitors BEZ235, BKM120, and GDC-0941 for 72 h, and cell death rates evaluated by trypan blue exclusion. (b) Western blot analysis after BKM120 and/or SMI-4a in DLD-1 cells treated with increasing doses of BKM120 and/o... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:29cb7f72db5499f088fb66ec","quotes":["Figure 5. Combinational effect of SMI-4a and PIK3CA inhibitors on CRC cell l... | [
"CLM:29cb7f72db5499f088fb66ec",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10461515"
] | [
"SPAN:209d3c7d1464e5d61b46ded6"
] | [] | [] | {"qa_id":"QA:8a833b41c21030d02dbe51fa","qa_group_id":"QAG:7c6bd6d24a2ab8903c810735","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"(a) DLD-1 ( PIK3CA MT) cells received the PIK3CA inhibitors BEZ235... |
QA:8b9a171b782de12b4acaf4ad | QAG:c751d4286948e5ca9500d363 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "For individual molecular features, both BMI and clothing-size was associated with an increased risk of KRAS mut [BMI: HR 5kg/m2 (95% CI): 1.31 (1.10–1.57), p -trend quartiles : 0.031; clothing-size: HR two sizes : 1.26 (1.03–1.53), p -trend quartiles : 0.229], but not ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3b3aeca425d49f4b747f8358","quotes":["For individual molecular features, both BMI and clothing-size were associate... | [
"CLM:3b3aeca425d49f4b747f8358",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:82d2927da9f7ac646ba65f9e"
] | [] | [] | {"qa_id":"QA:8b9a171b782de12b4acaf4ad","qa_group_id":"QAG:c751d4286948e5ca9500d363","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"For individual molecular features, both BMI and clothing-size was ... |
QA:8c0a5fb963d2e15cc705e99e | QAG:61896d7af9a3cd16cb063624 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "3 times/week) also inhibited tumor number ( P < 0.01) and load ( P < 0.01) (Fig. S16 ), validating its efficacy in spontaneous APC / KRAS -mutant CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:56e73cbb4db6a4dc53b26b7e","quotes":["Administration of R-IMPP to Apc Min/+ Kras G12D/+ Villin-Cre (50 mg/kg, i.p.... | [
"CLM:56e73cbb4db6a4dc53b26b7e",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:57b135f9e5225bd67fef81ea"
] | [] | [] | {"qa_id":"QA:8c0a5fb963d2e15cc705e99e","qa_group_id":"QAG:61896d7af9a3cd16cb063624","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"3 times/week) also inhibited tumor number ( P < 0.01) and load ( P... |
QA:8e894f5cac8966223bae0c7b | QAG:1de399ed79589bf23ce608e5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "The present study investigated the molecular mechanism of CPT promoted tumor suppression via alteration of glutamine and lipid metabolism in human pancreatic and colon cancer cell lines with mutant and wild-type KRAS"? Return the original wording with paper, Claim, and... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:83adff4cdf693e64e9c80e68","quotes":["The present study investigated the molecular mechanism of CPT-induced tumor ... | [
"CLM:83adff4cdf693e64e9c80e68",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC9339489"
] | [
"SPAN:11e1d944b54bf270c10a362e"
] | [] | [] | {"qa_id":"QA:8e894f5cac8966223bae0c7b","qa_group_id":"QAG:1de399ed79589bf23ce608e5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"The present study investigated the molecular mechanism of CPT prom... |
QA:8ed2428c0e1306043c380918 | QAG:9e57304bbf7870fbeff2fd47 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "These results indicated that cetuximab decreased the activation of Nrf2/HO-1 in RSL3-treated cells, which could in turn increased RSL3-induced lipid ROS and MDA levels"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:bf904233f7f3d1179456d195","quotes":["These results indicated that cetuximab decreased the activation of Nrf2/HO-1... | [
"CLM:bf904233f7f3d1179456d195",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:6aff27befbbab67d60a8cbf1",
"SPAN:cc8eb6cee7de699adf6a5aa9"
] | [] | [] | {"qa_id":"QA:8ed2428c0e1306043c380918","qa_group_id":"QAG:9e57304bbf7870fbeff2fd47","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"These results indicated that cetuximab decreased the activation of... |
QA:900af99357b7fcf6640a61b6 | QAG:3c9a5704e10f4eabc1a9f904 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Kaplan-Meier curve revealed that PCSK9 high protein expression was associated with poor survival in specifically in APC / KRAS -mutant CRC ( P < 0.005), but not in APC -mutant only CRC, or the overall CRC cohort (Fig. 6H )"? Return the original wording with paper, Clai... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3b54e8294b52fdacc9035c61","quotes":["Kaplan-Meier curve revealed that PCSK9 high protein expression was associate... | [
"CLM:3b54e8294b52fdacc9035c61",
"CLM:a1552d3605252a136c5cd060"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:2141a3483c47f940fd8899ee"
] | [] | [] | {"qa_id":"QA:900af99357b7fcf6640a61b6","qa_group_id":"QAG:3c9a5704e10f4eabc1a9f904","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Kaplan-Meier curve revealed that PCSK9 high protein expression was... |
QA:9430f80b44ac4bf5dc123ed4 | QAG:b6c00024818cf682f9e6734a | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Knockdown of GRB7 induced cell apoptosis and re sensitized to MEKi by attenuating the efficient activation of the RTK pathway"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:23b9228bf192701f3f6e4a11","quotes":["Knockdown of GRB7 induced cell apoptosis and re-sensitized CRC cells to MEKi... | [
"CLM:23b9228bf192701f3f6e4a11",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8732282"
] | [
"SPAN:6de01a540ebf467f890963b8"
] | [] | [] | {"qa_id":"QA:9430f80b44ac4bf5dc123ed4","qa_group_id":"QAG:b6c00024818cf682f9e6734a","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Knockdown of GRB7 induced cell apoptosis and re sensitized to MEKi... |
QA:95884b8b9f25fb01e0ab6445 | QAG:c2c08d66427d2b868e2dc203 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Pancreatic cancer patients with non-aneuploid copy number were predicted to be less sensitive to KRAS loss than patients with copy number aberration ( Fig 4C )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance require... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:627ea901a3635075e7e2211d","quotes":["Pancreatic cancer patients with non-aneuploid copy number were predicted to ... | [
"CLM:627ea901a3635075e7e2211d",
"CLM:02548fb255630e1212583b71"
] | [
"PMCID:PMC10187917"
] | [
"SPAN:7e5fd18da33f4203817618f5"
] | [] | [] | {"qa_id":"QA:95884b8b9f25fb01e0ab6445","qa_group_id":"QAG:c2c08d66427d2b868e2dc203","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Pancreatic cancer patients with non-aneuploid copy number were pre... |
QA:962b6cd1e6184300bf3021f5 | QAG:e085f41a502adea725dc7c79 | provenance_qa | paper_evidence_availability | provenance_qa | G009 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8905794? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC8905794","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC8905794"
] | [] | [] | [] | {"qa_id":"QA:962b6cd1e6184300bf3021f5","qa_group_id":"QAG:e085f41a502adea725dc7c79","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G009","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC8905794... |
QA:96a63361dadf5cee078b9e7d | QAG:aae9ce3df1d58e3c3817c67b | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "The growth suppression activity of MIR143#12 was higher than colorectal cancer cells than in pancreatic cancer cells, which may reflect the decreases induced in expression levels of MIR143"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:05b246c504dd385255b6956f","quotes":["The growth suppression activity of MIR143#12 was higher in colorectal cancer... | [
"CLM:05b246c504dd385255b6956f",
"CLM:55e0765cb3287e53f9c24e73"
] | [
"PMCID:PMC9507988"
] | [
"SPAN:0bf26eaa0b8e92a6a5ce1bd0"
] | [] | [] | {"qa_id":"QA:96a63361dadf5cee078b9e7d","qa_group_id":"QAG:aae9ce3df1d58e3c3817c67b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"The growth suppression activity of MIR143#12 was higher than color... |
QA:99451f05d692b43359898d3f | QAG:971000c33189beb37d29fd78 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Consistent with our observations in mice where RGX-202-01–mediated suppression of creatine uptake in tumors and tissues led to increased circulating and urinary excretion levels of creatine, we observed that patient serum and urine creatine levels increased upon RGX-20... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ac4c3c21a1a588c42757bccb","quotes":["Consistent with our observations in mice where RGX-202-01–mediated suppressi... | [
"CLM:ac4c3c21a1a588c42757bccb",
"CLM:03cfb269a9159ad24fb4ab8b"
] | [
"PMCID:PMC8494442"
] | [
"SPAN:d3a77cd6d1d7c61eeac4317b"
] | [] | [] | {"qa_id":"QA:99451f05d692b43359898d3f","qa_group_id":"QAG:971000c33189beb37d29fd78","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Consistent with our observations in mice where RGX-202-01–mediated... |
QA:99d48d91ee23fb04129c6afb | QAG:3bedd0b89a69e912e378afa2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Expression of BIM was also acutely increased following AZ’1569 treatment in all KRAS G12C MT colorectal cancer cell lines—in particular, the RW7213 and C106 cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ec1cb7e9cacb08724a112b8c","quotes":["Expression of BIM was also acutely increased following AZ’1569 treatment in ... | [
"CLM:ec1cb7e9cacb08724a112b8c",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9808374"
] | [
"SPAN:c2eafb58ca11b83312547f36"
] | [] | [] | {"qa_id":"QA:99d48d91ee23fb04129c6afb","qa_group_id":"QAG:3bedd0b89a69e912e378afa2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Expression of BIM was also acutely increased following AZ’1569 tre... |
QA:9b067d6fd366e326896ca2f2 | QAG:6a223127538b187bf776180d | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "When applied to TCGA datasets, specific subpopulations such as the invasive subtype in colorectal cancer and copy number high pancreatic adenocarcinoma were predicted to have higher KRAS dependency"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9f8de40d36a7e0a10f6919e7","quotes":["When applied to TCGA datasets, specific subpopulations such as the invasive ... | [
"CLM:9f8de40d36a7e0a10f6919e7",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC10187917"
] | [
"SPAN:2c77db3093ce4b5871fa5596"
] | [] | [] | {"qa_id":"QA:9b067d6fd366e326896ca2f2","qa_group_id":"QAG:6a223127538b187bf776180d","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"When applied to TCGA datasets, specific subpopulations such as the... |
QA:9d9866e6d07f0ab02d9d7bb3 | QAG:3dfc995f6ab5c2716fa5b82c | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "For treatment studies, Apc min/+ Kras G12D Villin-Cre male mice received vehicle (PBS) or R-IMPP (50 mg/kg in PBS, i.p., 3 times a week) from week 4 to week 7. Mice were sacrificed on week 7 and tumor number and size were measured"? Return the original wording with pap... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:66f18292748c51cd903bf8b3","quotes":["For metabolomic assays, 7-weeks-old male Apc min/+ Kras G12D Villin-Cre male... | [
"CLM:66f18292748c51cd903bf8b3",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:ce9b205d5e678b133f7c61d2"
] | [] | [] | {"qa_id":"QA:9d9866e6d07f0ab02d9d7bb3","qa_group_id":"QAG:3dfc995f6ab5c2716fa5b82c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"For treatment studies, Apc min/+ Kras G12D Villin-Cre male mice re... |
QA:9dd8d476133b37ed220fd3c7 | QAG:dfff1220f9747685da4c6d0f | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "41–44 PIM2 is well associated with hematological malignancies and lung cancer, 45 and loss of PIM3 by PIM3 shRNA promoted cell death, in pancreatic cancer and colon cancer cell lines"? Return the original wording with paper, Claim, and Evidence Span references.
Integr... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7c9856b9f3e9706035745878","quotes":["41–44 PIM2 is well associated with hematological malignancies and lung cance... | [
"CLM:7c9856b9f3e9706035745878",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10461515"
] | [
"SPAN:09a50d3e3aed98d5a56d3a38"
] | [] | [] | {"qa_id":"QA:9dd8d476133b37ed220fd3c7","qa_group_id":"QAG:dfff1220f9747685da4c6d0f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"41–44 PIM2 is well associated with hematological malignancies and ... |
QA:9fd3979f131aaca5cfb92c00 | QAG:1614e12f29ef55d210f4c508 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "In colorectal cancer, all the tumor types being treated were adenocarcinoma and all patients received a modified standard cytotoxic chemotherapy (78.4%) or additional EGFR monoclonal antibody cetuximab (21.6%)"? Return the original wording with paper, Claim, and Eviden... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:152853630a9440a2ad3a939b","quotes":["In colorectal cancer, all the tumor types being treated were adenocarcinoma ... | [
"CLM:152853630a9440a2ad3a939b",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8987589"
] | [
"SPAN:1c964f5032cd4810d86fbfce"
] | [] | [] | {"qa_id":"QA:9fd3979f131aaca5cfb92c00","qa_group_id":"QAG:1614e12f29ef55d210f4c508","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"In colorectal cancer, all the tumor types being treated were adeno... |
QA:a019c46a0bedec0cd4981280 | QAG:0bbc3e261a6ea51b4afc4d63 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "We determined that treatment with cetuximab increased the cytotoxicity of RSL3 in KRAS-mutated CRC cells and promoted RSL3-induced ferroptosis by suppressing Nrf2/HO-1 expression"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:178d3dfe9b9beb6ba395173e","quotes":["We determined that treatment with cetuximab significantly enhanced the cytot... | [
"CLM:178d3dfe9b9beb6ba395173e",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:cc8eb6cee7de699adf6a5aa9"
] | [] | [] | {"qa_id":"QA:a019c46a0bedec0cd4981280","qa_group_id":"QAG:0bbc3e261a6ea51b4afc4d63","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"We determined that treatment with cetuximab increased the cytotoxi... |
QA:a1412adcbcd5c7639da15bc2 | QAG:9d568d1a121bb4a794532ca9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "These results indicate that ferroptosis might be promoted after co-treatment with RSL3 and cetuximab in KRAS mutant CRC cell lines"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact suppo... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f116ff7596e9af9e0d9136fe","quotes":["These results indicate that ferroptosis might be promoted after co-treatment... | [
"CLM:f116ff7596e9af9e0d9136fe",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:0213a2dbff38ad55f825e0dc"
] | [] | [] | {"qa_id":"QA:a1412adcbcd5c7639da15bc2","qa_group_id":"QAG:9d568d1a121bb4a794532ca9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"These results indicate that ferroptosis might be promoted after co... |
QA:a1ec74ef0c7a864f16372dc6 | QAG:7ba24dfb075b42b55a43dc5e | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Tryptophanyl-tRNA synthetase (TrpRS) belongs to the aminoacyl-tRNA synthetase family, in addition to protein synthesis is involved in cytokine activity in inflammatory signaling and angiogenesis pathways, and is promoted by IFN γ and regulated by the p53 gene, causing ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:da4d2653e04b5c00ba823029","quotes":["Tryptophanyl-tRNA synthetase (TrpRS) belongs to the aminoacyl-tRNA synthetas... | [
"CLM:da4d2653e04b5c00ba823029",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8616688"
] | [
"SPAN:196ef5df293878a72eafb327"
] | [] | [] | {"qa_id":"QA:a1ec74ef0c7a864f16372dc6","qa_group_id":"QAG:7ba24dfb075b42b55a43dc5e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Tryptophanyl-tRNA synthetase (TrpRS) belongs to the aminoacyl-tRNA... |
QA:a2bf41a0f487c7d1b5bbad8c | QAG:a9e36004d2228d01c98255dd | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "We therefore dismissed them as drivers of cell proliferation in this model of CET resistance and focused on other hallmarks of cancer that drive disease progression, such as cell migration, as EPHA2 is known to regulate cell migration and was associated with elevated m... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:667aeea332d22fc98f8a7cb3","quotes":["We therefore dismissed them as drivers of cell proliferation in this model o... | [
"CLM:667aeea332d22fc98f8a7cb3",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC9931833"
] | [
"SPAN:66787798aef18ba3246d6df6"
] | [] | [] | {"qa_id":"QA:a2bf41a0f487c7d1b5bbad8c","qa_group_id":"QAG:a9e36004d2228d01c98255dd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"We therefore dismissed them as drivers of cell proliferation in th... |
QA:a33fd57c3dda11384bc69972 | QAG:f33c159db081bc884c4d0df8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "shPcsk9 inhibited proliferation of Apc Min/+ Kras G12D/+ Villin-Cre tumor organoids in Matrigel (Fig. S13 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6483dcb884c21188fcbe2173","quotes":["We also tested the effect of PCSK9 loss ex vivo in primary CRC organoids iso... | [
"CLM:6483dcb884c21188fcbe2173",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:955526f0245471a4fc5b29d2"
] | [] | [] | {"qa_id":"QA:a33fd57c3dda11384bc69972","qa_group_id":"QAG:f33c159db081bc884c4d0df8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"shPcsk9 inhibited proliferation of Apc Min/+ Kras G12D/+ Villin-Cr... |
QA:a52219f2850116a9f5e3d0bf | QAG:a13006f58357738442e3f8d0 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "(G–J) WB result showing that RYR2 or S107 treatment decreased BACH1 levels in different CRC cell lines"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Cl... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6f959d461822d6b3d042d38b","quotes":["(F) Bar plot showing relative luciferase activity of HCT116 cells. *** P < 0... | [
"CLM:6f959d461822d6b3d042d38b",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10061290"
] | [
"SPAN:c7db6e8cc37afeca69737a18"
] | [] | [] | {"qa_id":"QA:a52219f2850116a9f5e3d0bf","qa_group_id":"QAG:a13006f58357738442e3f8d0","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"(G–J) WB result showing that RYR2 or S107 treatment decreased BACH... |
QA:a536933ece3dd004060d5c93 | QAG:fc3cc561aeab1b0f925e2917 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "2 Cetuximab treatment enhances RSL3 promoted ferroptosis in KRAS mutant CRC cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evidence Spa... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:445791a9161b478698baaae7","quotes":["Fig. 2 Cetuximab treatment enhances RSL3-induced ferroptosis in KRAS mutant ... | [
"CLM:445791a9161b478698baaae7",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:8cd34efc51ff4d4730e2a38e"
] | [] | [] | {"qa_id":"QA:a536933ece3dd004060d5c93","qa_group_id":"QAG:fc3cc561aeab1b0f925e2917","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"2 Cetuximab treatment enhances RSL3 promoted ferroptosis in KRAS m... |
QA:a69a037f20cc5d45d99907ec | QAG:d69325f3555b92ce7b6c1174 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Occupational energy expenditure was associated with a decreased risk of overall colon cancer in men (Table 5 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2a0ba71f28b97c3a880f4efd","quotes":["Occupational energy expenditure was associated with a decreased risk of over... | [
"CLM:2a0ba71f28b97c3a880f4efd",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:50eac940af9428c2c777edcb"
] | [] | [] | {"qa_id":"QA:a69a037f20cc5d45d99907ec","qa_group_id":"QAG:d69325f3555b92ce7b6c1174","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Occupational energy expenditure was associated with a decreased ri... |
QA:aa292e274426b38cb833e89e | QAG:ba635b7690d507e8d6f4e6ff | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Patients who were diagnosed with metastatic disease greater than 90 days prior to their first visit within the FH network or received their FMI report greater than 60 days after their last FH visit date were excluded to ensure all therapies received prior to CGP were c... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:07f77a4f2d6038063b9e7451","quotes":["Patients who were diagnosed with metastatic disease greater than 90 days pri... | [
"CLM:07f77a4f2d6038063b9e7451",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9734185"
] | [
"SPAN:3ffb750f81c928e9b059c664",
"SPAN:6d18dccaa621054a6bde6b73"
] | [] | [] | {"qa_id":"QA:aa292e274426b38cb833e89e","qa_group_id":"QAG:ba635b7690d507e8d6f4e6ff","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Patients who were diagnosed with metastatic disease greater than 9... |
QA:ac53b7b69d2fd70bece2ec9f | QAG:21005868b32e555b217e3ef5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Also, overexpression of HO-1 reversed the growth inhibition promoted by cetuximab and RSL3 combination treatment in CRC cells (Fig. 4E, F )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the ex... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8f01b4982cc667eb9f829ec6","quotes":["Also, overexpression of HO-1 reversed the growth inhibition induced by cetux... | [
"CLM:8f01b4982cc667eb9f829ec6",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:86b682d1484743e880bd9e80"
] | [] | [] | {"qa_id":"QA:ac53b7b69d2fd70bece2ec9f","qa_group_id":"QAG:21005868b32e555b217e3ef5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Also, overexpression of HO-1 reversed the growth inhibition promot... |
QA:aec737efa2efceac6daef203 | QAG:1157b185c519d7b7674b5ff2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Cetuximab inhibited the Nrf2/HO-1 pathway via p38 MAPK activation and then regulated the sensitivity to RSL3 in KRAS mutant CRC cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact su... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:50ad00c37bc4f2ef81dbb640","quotes":["Cetuximab inhibited the Nrf2/HO-1 pathway via p38 MAPK activation and then r... | [
"CLM:50ad00c37bc4f2ef81dbb640",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:945c6824a32626a26a52682d"
] | [] | [] | {"qa_id":"QA:aec737efa2efceac6daef203","qa_group_id":"QAG:1157b185c519d7b7674b5ff2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Cetuximab inhibited the Nrf2/HO-1 pathway via p38 MAPK activation ... |
QA:af95b53af8f2d074a40599fb | QAG:6aa3ebfe9eead009eb9012e4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "A total of 195 patients diagnosed pathologically with colorectal cancer were enrolled in this study"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7e09367444b29c7d3dc3870a","quotes":["2.2. A total of 195 patients diagnosed pathologically with colorectal cancer... | [
"CLM:7e09367444b29c7d3dc3870a",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10061290"
] | [
"SPAN:a15a1a53830b36ef60a042d4"
] | [] | [] | {"qa_id":"QA:af95b53af8f2d074a40599fb","qa_group_id":"QAG:6aa3ebfe9eead009eb9012e4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"A total of 195 patients diagnosed pathologically with colorectal c... |
QA:b00ef88bc08fd631436b67d3 | QAG:504b045e21eba936da811e0c | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Interestingly, the combination of WNT974 and ART decreased KRAS protein levels (Fig. 1 B) but did not affect NRAS and HRAS (Fig. 1 B) in the CRC cells when compared to WNT974 or ART mono-treatments"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2d83355fedd5a15ba7813164","quotes":["The combination of WNT974 and ART exhibited synergi... | [
"CLM:2d83355fedd5a15ba7813164",
"CLM:3cd4082a1fbc3057f3124cf1",
"CLM:47a6baee3e3570d654ce636b"
] | [
"PMCID:PMC8934478",
"PMCID:PMC6952822"
] | [
"SPAN:0bcef78aff36ea90c25d5ac0",
"SPAN:71fa4b4e5d1b21f30986ec9f"
] | [
"ASC2:637ac39c9fbe09462bc2e414"
] | [
"HYP:DCH:ce19ae75ce90d43e12be2497"
] | {"qa_id":"QA:b00ef88bc08fd631436b67d3","qa_group_id":"QAG:504b045e21eba936da811e0c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Interestingly, the combination of WNT974 and ART decreased KRAS pr... |
QA:b08ae0284f909281e4ba844c | QAG:df9d65ad7e332b450aef91ed | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Moreover, CPT treatment decreased glutamine and lipid metabolism in the MIAPaCa-2 pancreatic cancer cell line containing mutant KRAS"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact sup... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:55f8aaf9a11a04cbf3e7eb3c","quotes":["Moreover, CPT treatment reduced glutamine and lipid metabolism in the MIAPaC... | [
"CLM:55f8aaf9a11a04cbf3e7eb3c",
"CLM:02548fb255630e1212583b71"
] | [
"PMCID:PMC9339489"
] | [
"SPAN:0f9636b6b60ff1e921dc9489"
] | [] | [] | {"qa_id":"QA:b08ae0284f909281e4ba844c","qa_group_id":"QAG:df9d65ad7e332b450aef91ed","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Moreover, CPT treatment decreased glutamine and lipid metabolism i... |
QA:b152bf8596a4a91fdd1c6b3f | QAG:84bed5d5c02071d621047f59 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "A cohort of 18 lung cancer patients received EGFR TKI or cytotoxic chemotherapy, and a cohort of 37 colorectal cancer patients was treated with EGFR monoclonal antibody or cytotoxic chemotherapy alone"? Return the original wording with paper, Claim, and Evidence Span r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1c9d16b0b7b55a94f69fc4e1","quotes":["A cohort of 18 lung cancer patients was treated with EGFR TKI or cytotoxic c... | [
"CLM:1c9d16b0b7b55a94f69fc4e1",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8987589"
] | [
"SPAN:4241181cba96ff643932c618"
] | [] | [] | {"qa_id":"QA:b152bf8596a4a91fdd1c6b3f","qa_group_id":"QAG:84bed5d5c02071d621047f59","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"A cohort of 18 lung cancer patients received EGFR TKI or cytotoxic... |
QA:b25e3c56f5a1b379072a09d3 | QAG:5a7112cd36c79a5bd1bfe791 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Specific Mutations in KRAS Codon 12 was associated with Worse Overall Survival in Patients with Advanced and Recurrent Colorectal Cancer"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:732feca289d183efac0c506a","quotes":["Specific Mutations in KRAS Codon 12 Are Associated with Worse Overall Surviv... | [
"CLM:732feca289d183efac0c506a",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC8696016"
] | [
"SPAN:14ed74486e76a20d34734a2d"
] | [] | [] | {"qa_id":"QA:b25e3c56f5a1b379072a09d3","qa_group_id":"QAG:5a7112cd36c79a5bd1bfe791","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Specific Mutations in KRAS Codon 12 was associated with Worse Over... |
QA:b456f975043c0f2a4769f4b2 | QAG:1d842de785b28ca724b53bde | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Single-agent divarasib treatment at 400 mg achieved a confirmed objective response rate (ORR) of 56.4% in patients with non-small cell lung cancer and 35.9% in patients with CRC, with a median progression-free survival (PFS) of 13.1 and 6.9 months, respectively 11"? Re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ed326732a8b6fd6aa7821e69","quotes":["Single-agent divarasib treatment at 400 mg achieved a confirmed objective re... | [
"CLM:ed326732a8b6fd6aa7821e69",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10803265"
] | [
"SPAN:7cec364cee440be17c1417d1"
] | [] | [] | {"qa_id":"QA:b456f975043c0f2a4769f4b2","qa_group_id":"QAG:1d842de785b28ca724b53bde","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Single-agent divarasib treatment at 400 mg achieved a confirmed ob... |
QA:b50789b2b1216c192b2cdb72 | QAG:15a2982554780a5e068b726f | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Conversely, inhibition of EGFR markedly increased sensitivity to AZ’1569 in all KRAS G12C MT colorectal cancer cells, supporting the findings of a recent study ( 12 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:80376b4edb77787d4a5f5dac","quotes":["Conversely, inhibition of EGFR markedly enhanced se... | [
"CLM:80376b4edb77787d4a5f5dac",
"CLM:3cd4082a1fbc3057f3124cf1",
"CLM:60cd0128ecb2baee335356c9",
"CLM:c9d8940a9ac365d6ac3f7783",
"CLM:e4939b3dfe4db64ed7650302"
] | [
"PMCID:PMC9808374",
"PMID:37870968",
"PMCID:PMC9507988"
] | [
"SPAN:d77dd331465f38eb94409a73",
"SPAN:42b9db74ce87fa931f8ae655",
"SPAN:5f4c1f851754fb19a7a8b8ca",
"SPAN:ccecf34a32503a55d19ccfbd"
] | [
"ASC2:4394f9a6442e6068caff9c39",
"ASC2:458b0b815681b531389c67b2"
] | [
"HYP:DCH:2a78493b95a923678ae6d925"
] | {"qa_id":"QA:b50789b2b1216c192b2cdb72","qa_group_id":"QAG:15a2982554780a5e068b726f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Conversely, inhibition of EGFR markedly increased sensitivity to A... |
QA:b66a5e30fea0dbc3d4ced406 | QAG:c4fcc7693e6ac3cb6f552ab5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "PCSK9 inhibitors, PF-0644846 and R-IMPP, dose-dependently inhibited protein expression of mature SREBP2 and HMGCR in APC / KRAS -mutant CRC cells (Fig. 3D )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requiremen... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:eb44c0b8d6729d84b23745e0","quotes":["PCSK9 inhibitors, PF-0644846 and R-IMPP, dose-dependently suppressed protein... | [
"CLM:eb44c0b8d6729d84b23745e0",
"CLM:a1552d3605252a136c5cd060"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:9611ab758bcf5b551eb5e77f"
] | [] | [] | {"qa_id":"QA:b66a5e30fea0dbc3d4ced406","qa_group_id":"QAG:c4fcc7693e6ac3cb6f552ab5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"PCSK9 inhibitors, PF-0644846 and R-IMPP, dose-dependently inhibite... |
QA:b6a90bb46eaac72bb364b6f6 | QAG:79d773a254a239f85fbc1e39 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "A cohort of 18 lung cancer patients was treated with EGFR TKI or cytotoxic chemotherapy, and a cohort of 37 colorectal cancer patients received EGFR monoclonal antibody or cytotoxic chemotherapy alone"? Return the original wording with paper, Claim, and Evidence Span r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0dbec664ad230f2c3589f1a0","quotes":["A cohort of 18 lung cancer patients was treated with EGFR TKI or cytotoxic c... | [
"CLM:0dbec664ad230f2c3589f1a0",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8987589"
] | [
"SPAN:4241181cba96ff643932c618"
] | [] | [] | {"qa_id":"QA:b6a90bb46eaac72bb364b6f6","qa_group_id":"QAG:79d773a254a239f85fbc1e39","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"A cohort of 18 lung cancer patients was treated with EGFR TKI or c... |
QA:b91614e8259d631d1c7e5806 | QAG:f1c9daea491445a5b0840ad8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "These results indicated that cetuximab decreased the activation of Nrf2/HO-1 in RSL3-treated cells, which could in turn increased RSL3 promoted lipid ROS and MDA levels"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenanc... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f96415cac1b046e4e84e3c63","quotes":["These results indicated that cetuximab decreased the activation of Nrf2/HO-1... | [
"CLM:f96415cac1b046e4e84e3c63",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:6aff27befbbab67d60a8cbf1",
"SPAN:cc8eb6cee7de699adf6a5aa9"
] | [] | [] | {"qa_id":"QA:b91614e8259d631d1c7e5806","qa_group_id":"QAG:f1c9daea491445a5b0840ad8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"These results indicated that cetuximab decreased the activation of... |
QA:bad80b3397006f6de67c11be | QAG:5c2205175c44654726e4829e | provenance_qa | paper_evidence_availability | provenance_qa | G009 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9908297? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9908297","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9908297"
] | [] | [] | [] | {"qa_id":"QA:bad80b3397006f6de67c11be","qa_group_id":"QAG:5c2205175c44654726e4829e","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G009","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9908297... |
QA:bbdf3c5c49258a191ea633bc | QAG:da5f83ed62ceb1368d11edaf | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Loss-of-function and gain-of-function assays validated that GRB7 potently sensitized to MEK inhibitors through the RTK pathway"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supportin... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:8dbb13ee0e6ff1d31f0e412b","quotes":["Loss-of-function and gain-of-function assays validated that GRB7 potently re... | [
"CLM:8dbb13ee0e6ff1d31f0e412b",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8732282"
] | [
"SPAN:e86a2ccd0dfb8808d158458a"
] | [] | [] | {"qa_id":"QA:bbdf3c5c49258a191ea633bc","qa_group_id":"QAG:da5f83ed62ceb1368d11edaf","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Loss-of-function and gain-of-function assays validated that GRB7 p... |
QA:bde8c26cccc8b95670042cc5 | QAG:6d7cefabeb621fd687efcbb8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "These results demonstrate that elevated tumoral CKB mRNA and protein expression levels predicted enhanced responsiveness to SLC6A8 inhibition by RGX-202, consistent with CKB being an upstream component of the CKB/SLC6A8 phosphocreatine metabolic axis in CRC and a gene ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9537caf8a6101f34c47d4bdc","quotes":["These results demonstrate that elevated tumoral CKB mRNA and protein express... | [
"CLM:9537caf8a6101f34c47d4bdc",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8494442"
] | [
"SPAN:29a5bb53e4b0c68fc75d9fa7"
] | [] | [] | {"qa_id":"QA:bde8c26cccc8b95670042cc5","qa_group_id":"QAG:6d7cefabeb621fd687efcbb8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"These results demonstrate that elevated tumoral CKB mRNA and prote... |
QA:be2a0902df176c3fc186761e | QAG:9796a5fac3320676a2808f98 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "1 B) but did not improve NRAS and HRAS (Fig. 1 B) in the CRC cells when compared to WNT974 or ART mono-treatments"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:80c36603eab203cec14d0445","quotes":["The combination of WNT974 and ART exhibited synergistic effect in reducing C... | [
"CLM:80c36603eab203cec14d0445",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8934478"
] | [
"SPAN:0bcef78aff36ea90c25d5ac0"
] | [] | [] | {"qa_id":"QA:be2a0902df176c3fc186761e","qa_group_id":"QAG:9796a5fac3320676a2808f98","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"1 B) but did not improve NRAS and HRAS (Fig. 1 B) in the CRC cells... |
QA:beee8ef945c79cde818e6b4b | QAG:4a3d332767b48a53274f9ed8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "RGX-202-01 also elicited increased antitumor efficacy in combination with 5-FU and irinotecan, a standard-of-care regimen for metastatic CRC (fig. S3A)"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: r... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9ef143027ad6d59499ab91dc","quotes":["RGX-202-01 also elicited enhanced antitumor efficacy in combination with 5-F... | [
"CLM:9ef143027ad6d59499ab91dc",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8494442"
] | [
"SPAN:4afc54635bd94bd45768b503"
] | [] | [] | {"qa_id":"QA:beee8ef945c79cde818e6b4b","qa_group_id":"QAG:4a3d332767b48a53274f9ed8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"RGX-202-01 also elicited increased antitumor efficacy in combinati... |
QA:c042b0ffeb65e2ab3726d03a | QAG:aaacc9c131b2f97f99b8fd2c | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "These results indicated that cetuximab decreased the activation of Nrf2/HO-1 in RSL3-treated cells, which could in turn increased RSL3-induced lipid ROS and MDA levels"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a26d3aa2336e0e76354b25eb","quotes":["These results indicated that cetuximab decreased the activation of Nrf2/HO-1... | [
"CLM:a26d3aa2336e0e76354b25eb",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:6aff27befbbab67d60a8cbf1",
"SPAN:cc8eb6cee7de699adf6a5aa9"
] | [] | [] | {"qa_id":"QA:c042b0ffeb65e2ab3726d03a","qa_group_id":"QAG:aaacc9c131b2f97f99b8fd2c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"These results indicated that cetuximab decreased the activation of... |
QA:c0bb3935760e052f28322d95 | QAG:c7927350f57e5617d17ae99e | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "We also evaluated the effect of APC -loss and Kras G12D on cholesterol metabolism-related gene expression in genetic CRC mice models (sh Renilla , sh Apc and sh Apc-Kras G12D ) ( GSE67186 ), showing that PCSK9 and cholesterol biosynthesis genes were promoted in sh Apc-... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:24bf1ea734beab4b59839818","quotes":["We also evaluated the effect of APC -loss and Kras ... | [
"CLM:24bf1ea734beab4b59839818",
"CLM:55e0765cb3287e53f9c24e73",
"CLM:c9d8940a9ac365d6ac3f7783"
] | [
"PMCID:PMC9270407",
"PMCID:PMC9507988"
] | [
"SPAN:4217b67375f435f392910688",
"SPAN:5f4c1f851754fb19a7a8b8ca"
] | [
"ASC2:d5bdad6b8dccb0aba7222aed"
] | [
"HYP:DCH:e0e53b5b29ee3e211ce3cde9"
] | {"qa_id":"QA:c0bb3935760e052f28322d95","qa_group_id":"QAG:c7927350f57e5617d17ae99e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"We also evaluated the effect of APC -loss and Kras G12D on cholest... |
QA:c1bf7785b2f8ba8db2a07f2b | QAG:b6701e069fbb3ab84886c780 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Cetuximab promoted RSL3 promoted ferroptosis by inhibiting the Nrf2/HO-1 in KRAS mutant CRC cells, and this was further demonstrated in a xenograft nude mouse model"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:77d065fcbf5ec1ae57107238","quotes":["Cetuximab promoted RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 in K... | [
"CLM:77d065fcbf5ec1ae57107238",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:499c1c40d7a008d0de8e8995"
] | [] | [] | {"qa_id":"QA:c1bf7785b2f8ba8db2a07f2b","qa_group_id":"QAG:b6701e069fbb3ab84886c780","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Cetuximab promoted RSL3 promoted ferroptosis by inhibiting the Nrf... |
QA:c1d2d5c334529fcb6f1f5ba3 | QAG:de3517492868dbbff3e5d7ca | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Furthermore, lower occupational sitting time was associated with a decreased risk of overall colon cancer in men (Table 5 ), and associations were slightly stronger for the all-wild-type + pMMR subgroup [HR <2 h/day (95% CI): 0.56 (0.38–0.81), p -trend categories : 0.0... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:20df5cdba72d87548efc9291","quotes":["Furthermore, lower occupational sitting time was associated with a decreased... | [
"CLM:20df5cdba72d87548efc9291",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:a18db79425ccde5bf72e64a5"
] | [] | [] | {"qa_id":"QA:c1d2d5c334529fcb6f1f5ba3","qa_group_id":"QAG:de3517492868dbbff3e5d7ca","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Furthermore, lower occupational sitting time was associated with a... |
QA:c2a7cabd7c0c875c84e04361 | QAG:0596fa8680b15d699b82e8b9 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Here, we further investigated whether cetuximab-mediated regulation of p38/Nrf2/HO-1 promotes RSL3 promoted ferroptosis and plays a pivotal role in overcoming drug resistance in KRAS mutant colorectal cancer (CRC)"? Return the original wording with paper, Claim, and Ev... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1f49030c58719ea8cbadf2bd","quotes":["Here, we further investigated whether cetuximab-med... | [
"CLM:1f49030c58719ea8cbadf2bd",
"CLM:1cba67a12cdd2f006af7d9e3",
"CLM:ea5672e3ca4128dffe7f4a26"
] | [
"PMCID:PMC8590697",
"PMCID:PMC9808374"
] | [
"SPAN:4fd73178d2846e134d78e377",
"SPAN:93f53410008a73cf886081a7"
] | [
"ASC2:9a6a2fbe5eb39bdc54e99616"
] | [
"HYP:DCH:f01026771f75145d8a168579"
] | {"qa_id":"QA:c2a7cabd7c0c875c84e04361","qa_group_id":"QAG:0596fa8680b15d699b82e8b9","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Here, we further investigated whether cetuximab-mediated regulatio... |
QA:c56c463439204e82a4365808 | QAG:bcc93f5322252eb6d719ce1c | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "The PROTACs (proteolysis targeting chimeras) dBET1 and MZ1 promoted degradation of BRD4 followed by a reduction in MYC expression and inhibition of CRC cell proliferation"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provena... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9cbde910c7a1bb5363224f56","quotes":["The PROTACs (proteolysis targeting chimeras) dBET1 and MZ1 induced degradati... | [
"CLM:9cbde910c7a1bb5363224f56",
"CLM:55e0765cb3287e53f9c24e73"
] | [
"PMCID:PMC8488304"
] | [
"SPAN:553537a03c77d1ff1ae6fab6"
] | [] | [] | {"qa_id":"QA:c56c463439204e82a4365808","qa_group_id":"QAG:bcc93f5322252eb6d719ce1c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"The PROTACs (proteolysis targeting chimeras) dBET1 and MZ1 promote... |
QA:c618a014bf9251d2b0a3e6a6 | QAG:450340fdd3ddb8216f816484 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Similarly, combination treatment with BI-2536 and AZD6244 synergistically promoted CRC cell apoptosis in HCT116 and SW480 cells after 48 h (Fig. 6C, D , and Supplementary Fig. S7E, F )"? Return the original wording with paper, Claim, and Evidence Span references.
Inte... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:74a74f8e98e43c4e05d8baca","quotes":["To further verify the results of RNAi, we interrupted the function of PLK1 w... | [
"CLM:74a74f8e98e43c4e05d8baca",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8732282"
] | [
"SPAN:312cdaf3418d8e65910a9e3c"
] | [] | [] | {"qa_id":"QA:c618a014bf9251d2b0a3e6a6","qa_group_id":"QAG:450340fdd3ddb8216f816484","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Similarly, combination treatment with BI-2536 and AZD6244 synergis... |
QA:ca0e874e68fab4678e723526 | QAG:0ca383cc9144d56bac31322c | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Human KRAS/NRAS/BRAF V600 -wild-type colorectal cancer cell lines with NF1 mutations displayed decreased NF1 mRNA or protein expression and were resistant to EGFR blockade by gefitinib or cetuximab"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0c691487875305cd83b08334","quotes":["Human KRAS/NRAS/BRAF V600 -wild-type colorectal can... | [
"CLM:0c691487875305cd83b08334",
"CLM:125bd56675f6596398baa1a9",
"CLM:104adc2eb5cd0e04de78a2b3"
] | [
"PMCID:PMC7611272",
"PMCID:PMC8987589"
] | [
"SPAN:9e6dab9a2b19f6c6ef78d095",
"SPAN:8ba3416f64c442003031306d"
] | [
"ASC2:697dc0b96646a11db96434b8"
] | [] | {"qa_id":"QA:ca0e874e68fab4678e723526","qa_group_id":"QAG:0ca383cc9144d56bac31322c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Human KRAS/NRAS/BRAF V600 -wild-type colorectal cancer cell lines ... |
QA:ca12155f148c61b67fab5888 | QAG:c619ff4463d63d4f823198c2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "D, KRASG12C MT colorectal cancer cells received AZ’1569 alone or combined with cetuximab or ABT-737 (0.25 μmol/L for C106, LIM2099, SNU1411; 0.5 μmol/L for SW837, V481, RW7213 and 2.5 μmol/L for SW1463) for 48 hours (24 hours for C106 cells) and PARP, cleaved C9, cleav... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:62b143baee9fbec3045e2869","quotes":["D, KRASG12C MT colorectal cancer cells were treated with AZ’1569 alone or co... | [
"CLM:62b143baee9fbec3045e2869",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9808374"
] | [
"SPAN:6c939a9d087166dee96180b5"
] | [] | [] | {"qa_id":"QA:ca12155f148c61b67fab5888","qa_group_id":"QAG:c619ff4463d63d4f823198c2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"D, KRASG12C MT colorectal cancer cells received AZ’1569 alone or c... |
QA:cb0cafe7cc2d9f98510674b1 | QAG:bca494b8dc01fdbcc3051ab6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Although less studied functionally and mechanistically, NRAS mutations was associated with worse prognosis and overall survival when compared to KRAS mutant- or wild type KRAS-driven metastatic CRC"? Return the original wording with paper, Claim, and Evidence Span refe... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:47a6baee3e3570d654ce636b","quotes":["Although less studied functionally and mechanistically, NRAS mutations have ... | [
"CLM:47a6baee3e3570d654ce636b",
"CLM:55e0765cb3287e53f9c24e73"
] | [
"PMCID:PMC6952822"
] | [
"SPAN:71fa4b4e5d1b21f30986ec9f"
] | [] | [] | {"qa_id":"QA:cb0cafe7cc2d9f98510674b1","qa_group_id":"QAG:bca494b8dc01fdbcc3051ab6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Although less studied functionally and mechanistically, NRAS mutat... |
QA:cb2db75c96159bcd09c4ef4f | QAG:cac5f174ec502faa19f629d5 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Mechanistically, we demonstrated that Nrf2/HO-1 is essential for cetuximab to promote RSL3 promoted ferroptosis in KRAS mutant CRC cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f6bca1393e1f3bfdf45a3883","quotes":["Mechanistically, we demonstrated that Nrf2/HO-1 is essential for cetuximab t... | [
"CLM:f6bca1393e1f3bfdf45a3883",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:884da3f9f35b48827e8e5dee"
] | [] | [] | {"qa_id":"QA:cb2db75c96159bcd09c4ef4f","qa_group_id":"QAG:cac5f174ec502faa19f629d5","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Mechanistically, we demonstrated that Nrf2/HO-1 is essential for c... |
QA:ccccd2eab03d967da8fd419d | QAG:35a87178a546ef66ae87c3d8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "A clinical trial reported that KRAS mutation did not improve overall survival in stage II/III colon cancer 25 , while others documented a negative impact of KRAS mutation on overall survival 26 – 28"? Return the original wording with paper, Claim, and Evidence Span ref... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c62bffce0cdb531117af11fe","quotes":["A clinical trial reported that KRAS mutation did not affect overall survival... | [
"CLM:c62bffce0cdb531117af11fe",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC10721872"
] | [
"SPAN:09252d15a8c52031d5a9ef04"
] | [] | [] | {"qa_id":"QA:ccccd2eab03d967da8fd419d","qa_group_id":"QAG:35a87178a546ef66ae87c3d8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"A clinical trial reported that KRAS mutation did not improve overa... |
QA:cf03992efdde870a33634ef2 | QAG:f83a163c888a5c0ea4b7caac | provenance_qa | paper_evidence_availability | provenance_qa | G009 | en | train | Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9870238? Explicitly abstain if it does not.
Integrated provenance requirements: report evidence availability or insufficiency without inventing missing full text. Keep each subtask answer separately identifiable... | {"answer_type":"integrated_provenance","embedded_answer_types":["paper_evidence_availability"],"exact_evidence_retrieval":null,"limited_evidence_retrieval":null,"paper_evidence_availability":{"answer_type":"explicit_evidence_abstention","paper_id":"PMCID:PMC9870238","verdict":"no_released_traceable_claim","reason":"No ... | [] | [
"PMCID:PMC9870238"
] | [] | [] | [] | {"qa_id":"QA:cf03992efdde870a33634ef2","qa_group_id":"QAG:f83a163c888a5c0ea4b7caac","qa_family":"provenance_qa","subtask_type":"paper_evidence_availability","language":"en","cluster_id":"G009","question":"Does the current traceable evidence dataset contain a usable Claim and exact source span for paper PMCID:PMC9870238... |
QA:cff755dbed3515955096e836 | QAG:72a5132f116a5222b97ae612 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "In contrast, non-occupational physical activity was associated with an increased risk of overall rectal cancer in men, which was stronger for the any-mutation/dMMR subgroup [HR >90vs≤30 min/day (95% CI): 3.32 (1.28–8.60), p -trend categories : 0.033], whereas no clear ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2a85af2bb3ecb42a7b988891","quotes":["In contrast, non-occupational physical activity was associated with an incre... | [
"CLM:2a85af2bb3ecb42a7b988891",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:4affcd1d88b2c2949ede9f82"
] | [] | [] | {"qa_id":"QA:cff755dbed3515955096e836","qa_group_id":"QAG:72a5132f116a5222b97ae612","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"In contrast, non-occupational physical activity was associated wit... |
QA:d1e580bb0a85f20fa72e21da | QAG:90351e9f5e007975117e3331 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Although these six channels share a similar function, it is intriguing to find that only high RyR2 expression predicted a poor prognosis in CRC (Fig. S5 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:2ba3a8f96c7ec13824f6cc55","quotes":["Although these six channels share a similar function, it is intriguing to fi... | [
"CLM:2ba3a8f96c7ec13824f6cc55",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10061290"
] | [
"SPAN:01aa0c8cfc1fc48f17563fd3"
] | [] | [] | {"qa_id":"QA:d1e580bb0a85f20fa72e21da","qa_group_id":"QAG:90351e9f5e007975117e3331","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Although these six channels share a similar function, it is intrig... |
QA:d21d60110402de8b2af85a5a | QAG:bdb222888c51c206d19a0cc4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Abstract DNA mismatch repair deficiency (dMMR) in metastatic colorectal cancer (mCRC) was associated with poor survival and a poor response to systemic treatment"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ff81313b5d796b7432ac5c3b","quotes":["Abstract DNA mismatch repair deficiency (dMMR) in metastatic colorectal canc... | [
"CLM:ff81313b5d796b7432ac5c3b",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8582471"
] | [
"SPAN:950bfd0d0a23f6fb4bd5aa43"
] | [] | [] | {"qa_id":"QA:d21d60110402de8b2af85a5a","qa_group_id":"QAG:bdb222888c51c206d19a0cc4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Abstract DNA mismatch repair deficiency (dMMR) in metastatic color... |
QA:d2f48ceed4b97473ae583e10 | QAG:6f4f6643c061d447f5121eeb | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "We aim to identify novel genetic alterations associated with drug resistance in lung cancer and colorectal cancer patients who received EGFR-targeted therapy and cytotoxic chemotherapy through whole exome sequencing (WES) of cfDNA"? Return the original wording with pap... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0c3fbaa571bc4394b16b3479","quotes":["We aim to identify novel genetic alterations associated with drug resistance... | [
"CLM:0c3fbaa571bc4394b16b3479",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8987589"
] | [
"SPAN:2d0f4d8e1905b7009dbe29a0"
] | [] | [] | {"qa_id":"QA:d2f48ceed4b97473ae583e10","qa_group_id":"QAG:6f4f6643c061d447f5121eeb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"We aim to identify novel genetic alterations associated with drug ... |
QA:d431d3c87baa9b79d67ddc27 | QAG:3f5192da608bf8ef24dfee33 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "β-catenin promoted thus PCSK9 represents a point of synergy between APC and KRAS in CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Eviden... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7e35abd944ca101a5016111d","quotes":["Mutant KRAS activates β-catenin 3 , as evidenced by increased nuclear active... | [
"CLM:7e35abd944ca101a5016111d",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:d5824515e2136bb24e2afe6b"
] | [] | [] | {"qa_id":"QA:d431d3c87baa9b79d67ddc27","qa_group_id":"QAG:3f5192da608bf8ef24dfee33","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"β-catenin promoted thus PCSK9 represents a point of synergy betwee... |
QA:d531b633384f09254109944d | QAG:e75d900b7967603dc00e22cd | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Interestingly, our study showed that pretreatment BIM levels was associated with sensitivity and apoptotic response to AZ’1569 in KRAS G12C MT colorectal cancer cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9050f13d5b951b8e71546945","quotes":["Interestingly, our study showed that pretreatment BIM levels were associated... | [
"CLM:9050f13d5b951b8e71546945",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC9808374"
] | [
"SPAN:33f0d8a1703c33c4d8f7d18d"
] | [] | [] | {"qa_id":"QA:d531b633384f09254109944d","qa_group_id":"QAG:e75d900b7967603dc00e22cd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Interestingly, our study showed that pretreatment BIM levels was a... |
QA:d6669049777c5a9ddf989907 | QAG:5f6510de4d6b2d7c1b787f09 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Consistent with our observations in mice where RGX-202-01–mediated suppression of creatine uptake in tumors and tissues led to increased circulating and urinary excretion levels of creatine, we observed that patient serum and urine creatine levels increased upon RGX-20... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e6114c43223da2da731bde5b","quotes":["Consistent with our observations in mice where RGX-202-01–mediated suppressi... | [
"CLM:e6114c43223da2da731bde5b",
"CLM:03cfb269a9159ad24fb4ab8b"
] | [
"PMCID:PMC8494442"
] | [
"SPAN:d3a77cd6d1d7c61eeac4317b"
] | [] | [] | {"qa_id":"QA:d6669049777c5a9ddf989907","qa_group_id":"QAG:5f6510de4d6b2d7c1b787f09","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Consistent with our observations in mice where RGX-202-01–mediated... |
QA:d668a9d2a1c66d40710173c6 | QAG:a527c74ac4dd020aea47f9d6 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Non-occupational physical activity was not associated with overall rectal cancer in women, and stratification on subgroups did not lead to clear associations (Tables 5 , 6 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prov... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:6be02e99a433447c5cf5cf04","quotes":["Non-occupational physical activity was not associated with overall rectal ca... | [
"CLM:6be02e99a433447c5cf5cf04",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:008921f194a208557d1c4766"
] | [] | [] | {"qa_id":"QA:d668a9d2a1c66d40710173c6","qa_group_id":"QAG:a527c74ac4dd020aea47f9d6","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Non-occupational physical activity was not associated with overall... |
QA:d6b9b3b0225402a57c2d0578 | QAG:1c18ba1296b7e8c1f26908db | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "PCSK9 predicted poor prognosis in CRC patients harboring APC / KRAS mutations, in line with the oncogenic function of PCSK9 in APC / KRAS -mutant CRC"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e9d7e2cde1c29464ae0665c5","quotes":["PCSK9 predicts poor prognosis in CRC patients harboring APC / KRAS mutations... | [
"CLM:e9d7e2cde1c29464ae0665c5",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:e963fd3c54b0b840e0cd0242"
] | [] | [] | {"qa_id":"QA:d6b9b3b0225402a57c2d0578","qa_group_id":"QAG:1c18ba1296b7e8c1f26908db","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"PCSK9 predicted poor prognosis in CRC patients harboring APC / KRA... |
QA:d72b0f1ffd9626b6b6cc0807 | QAG:a5cac95d8175f9274c891803 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Occupational physical activity was associated with a decreased risk of colon cancer for both combination subgroups in men, but associations were strongest for all-wild-type + pMMR tumors"? Return the original wording with paper, Claim, and Evidence Span references.
In... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:295e7e88ee2d3ede25b677c9","quotes":["Occupational physical activity was associated with a decreased risk of colon... | [
"CLM:295e7e88ee2d3ede25b677c9",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:5eab99c9562cc37cd22c5651"
] | [] | [] | {"qa_id":"QA:d72b0f1ffd9626b6b6cc0807","qa_group_id":"QAG:a5cac95d8175f9274c891803","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Occupational physical activity was associated with a decreased ris... |
QA:d7c4a8541a7bfa56cc7c42ea | QAG:111b815313b5e5d870a8c816 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "G PCSK9 protein expression is increased in CRC compared to adjacent normal tissues assessed by western blot"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with pape... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:9b1b6ac0185a42be9fb8032f","quotes":["G PCSK9 protein expression is increased in CRC compared to adjacent normal t... | [
"CLM:9b1b6ac0185a42be9fb8032f",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:4e635aa26a43c06f7be61e61"
] | [] | [] | {"qa_id":"QA:d7c4a8541a7bfa56cc7c42ea","qa_group_id":"QAG:111b815313b5e5d870a8c816","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"G PCSK9 protein expression is increased in CRC compared to adjacen... |
QA:dadb5e8d70ba60a797d66ae5 | QAG:359f93e6e781fe21bea646f8 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Although there was no significant difference between lung and colorectal cancer, mean cfDNA amount was higher than the group with larger size of residual tumor ( Supplementary Figure S1B )"? Return the original wording with paper, Claim, and Evidence Span references.
... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:a04d8426adefad41497d199f","quotes":["Although there was no significant difference between lung and colorectal can... | [
"CLM:a04d8426adefad41497d199f",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8987589"
] | [
"SPAN:4c773f12a5a3c328c8f91b0b"
] | [] | [] | {"qa_id":"QA:dadb5e8d70ba60a797d66ae5","qa_group_id":"QAG:359f93e6e781fe21bea646f8","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Although there was no significant difference between lung and colo... |
QA:dcf53f970a992e6f903e6fb4 | QAG:8053b50d6767059c92bc8cf3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Lastly, physical activity was associated with both MSS and MSI colon cancer in men, but only with MSS colon cancer in women (Slattery et al. 2000 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retur... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b9c20b0bd97c64d1a54ebba0","quotes":["Lastly, physical activity was associated with both MSS and MSI colon cancer ... | [
"CLM:b9c20b0bd97c64d1a54ebba0",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:37aca0fb1cbd3865b38f5bef"
] | [] | [] | {"qa_id":"QA:dcf53f970a992e6f903e6fb4","qa_group_id":"QAG:8053b50d6767059c92bc8cf3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Lastly, physical activity was associated with both MSS and MSI col... |
QA:dd5d3f7a5343224d86a13470 | QAG:05f9b628958747e028584489 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "D, KRAS G12C MT colorectal cancer cells received AZ’1569 alone or combined with cetuximab or ABT-737 (0.25 μmol/L for C106, LIM2099, SNU1411; 0.5 μmol/L for SW837, V481, RW7213 and 2.5 μmol/L for SW1463) for 48 hours (24 hours for C106 cells) and PARP, cleaved C9, clea... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e4939b3dfe4db64ed7650302","quotes":["D, KRAS G12C MT colorectal... | [
"CLM:e4939b3dfe4db64ed7650302",
"CLM:1cba67a12cdd2f006af7d9e3",
"CLM:513308b69f0351967d37a6ff",
"CLM:c9d8940a9ac365d6ac3f7783"
] | [
"PMCID:PMC9808374",
"PMCID:PMC10803265",
"PMCID:PMC9507988"
] | [
"SPAN:ccecf34a32503a55d19ccfbd",
"SPAN:e9fcda7b9b8748b3e2289d20",
"SPAN:5f4c1f851754fb19a7a8b8ca"
] | [
"ASC2:baef580ef57272f492a6394c",
"ASC2:458b0b815681b531389c67b2"
] | [
"HYP:DCH:912ae9d2ac3af3db1854ffe9",
"HYP:DCH:605eaf91e3c25ae0e7707761"
] | {"qa_id":"QA:dd5d3f7a5343224d86a13470","qa_group_id":"QAG:05f9b628958747e028584489","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"D, KRAS G12C MT colorectal cancer cells received AZ’1569 alone or ... |
QA:e1109c5ab32ec757283e7a31 | QAG:e60b7d256ed513f36fef61e3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Moreover, GGPS1 protein predicted the poor survival in APC / KRAS -mutant CRC ( P < 0.05) but not in APC -mutant CRC in Hong Kong cohort (Fig. S17 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: retu... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:b4de8f2f237919c0b105d3ad","quotes":["Moreover, GGPS1 protein predicts the poor survival in APC / KRAS -mutant CRC... | [
"CLM:b4de8f2f237919c0b105d3ad",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:39ff1816a8c1f122a569876a"
] | [] | [] | {"qa_id":"QA:e1109c5ab32ec757283e7a31","qa_group_id":"QAG:e60b7d256ed513f36fef61e3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Moreover, GGPS1 protein predicted the poor survival in APC / KRAS ... |
QA:e24e906b063dc570b9a89e96 | QAG:bf78113bb2eed31076f5224f | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "(c) HCT116 ( PIK3CA MT), DLD-1 ( PIK3CA MT), SW480 ( PIK3CA WT), and SW620 ( PIK3CA WT) CRC cell lines received increasing doses of BKM120 and/or 30 μM SMI-4a for 72 h"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:7ab4f95bd642e89640d99c91","quotes":["Beta-actin was used as a loading control. (c) HCT116 ( PIK3CA MT), DLD-1 ( P... | [
"CLM:7ab4f95bd642e89640d99c91",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10461515"
] | [
"SPAN:fa4255a88844d051b91e90aa"
] | [] | [] | {"qa_id":"QA:e24e906b063dc570b9a89e96","qa_group_id":"QAG:bf78113bb2eed31076f5224f","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"(c) HCT116 ( PIK3CA MT), DLD-1 ( PIK3CA MT), SW480 ( PIK3CA WT), a... |
QA:e3a9fd3e5d1ca3fb04184b18 | QAG:9e0a1a335accb35bbd243d85 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "These results are consistent with previous findings that EGFR downregulation after treatment with cetuximab or panitumumab predicted the antitumor effect in CRC and that HER2 amplification confers resistance to anti-EGFR therapy in CRC"? Return the original wording wit... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:f919c5d13335b1660a98a88c","quotes":["These results are consistent with previous findings... | [
"CLM:f919c5d13335b1660a98a88c",
"CLM:125bd56675f6596398baa1a9",
"CLM:104adc2eb5cd0e04de78a2b3"
] | [
"PMCID:PMC9161494",
"PMCID:PMC8987589"
] | [
"SPAN:797bc99e27febbbc112b7928",
"SPAN:8ba3416f64c442003031306d"
] | [
"ASC2:e738d4ec04bea080a1dedc05"
] | [
"HYP:DCH:6a2cc41cbd64c988fda83896"
] | {"qa_id":"QA:e3a9fd3e5d1ca3fb04184b18","qa_group_id":"QAG:9e0a1a335accb35bbd243d85","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"These results are consistent with previous findings that EGFR down... |
QA:e44e425f638c352f79609f04 | QAG:8eb7a212ab7f33469fc7179b | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "From January 2010 to December 2019, patients received chemotherapy (Lung cancer—EGFR TKI or Cytotoxic chemotherapy), (Colorectal cancer—Cytotoxic chemotherapy or Cetuximab) and total of 42 lung cancer patients and 63 colorectal cancer patient samples were used for this... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:104adc2eb5cd0e04de78a2b3","quotes":["From January 2010 to December 2019, patients were treated with chemotherapy ... | [
"CLM:104adc2eb5cd0e04de78a2b3",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8987589"
] | [
"SPAN:8ba3416f64c442003031306d"
] | [] | [] | {"qa_id":"QA:e44e425f638c352f79609f04","qa_group_id":"QAG:8eb7a212ab7f33469fc7179b","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"From January 2010 to December 2019, patients received chemotherapy... |
QA:e47a338786df5e86492c3511 | QAG:c61b4d5a3070d4fee865b951 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Later, it was demonstrated that activation of the Ras–MAPK–ETS2–p300 cascade led to GSK-3β overexpression in pancreatic cancer cells ( Zhang et al., 2011 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirement... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:dbfeefc80abcf05855dc2828","quotes":["Later, it was demonstrated that activation of the Ras–MAPK–ETS2–p300 cascade... | [
"CLM:dbfeefc80abcf05855dc2828",
"CLM:02548fb255630e1212583b71"
] | [
"PMCID:PMC8696016"
] | [
"SPAN:838083dcde4ce79316e6e23c"
] | [] | [] | {"qa_id":"QA:e47a338786df5e86492c3511","qa_group_id":"QAG:c61b4d5a3070d4fee865b951","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Later, it was demonstrated that activation of the Ras–MAPK–ETS2–p3... |
QA:e58669fed28c86f3aea3b1ab | QAG:5f00e88610e61fe20e41f5b3 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "In patients with CRC who had not received prior KRAS G12C inhibitor treatment, single-agent divarasib achieved a response rate of 35.9% 11 , while the combination of divarasib and cetuximab achieved a response rate of 62.5%"? Return the original wording with paper, Cla... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:e859432bf7f87473c46061c2","quotes":["In patients with CRC who had not received prior KRAS G12C inhibitor treatmen... | [
"CLM:e859432bf7f87473c46061c2",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC10803265"
] | [
"SPAN:e9fcda7b9b8748b3e2289d20"
] | [] | [] | {"qa_id":"QA:e58669fed28c86f3aea3b1ab","qa_group_id":"QAG:5f00e88610e61fe20e41f5b3","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"In patients with CRC who had not received prior KRAS G12C inhibito... |
QA:e58f1aadcdb8b97a0e237518 | QAG:3e76481e8cf36a8c39311068 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "The SW1463 model was resistant to single-agent navitoclax treatment and exhibited slowed but persistent growth when mice received AZ’8037 ( Fig. 5A )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: ret... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ee44c9fcc3a96a15a8ad27e7","quotes":["We selected two different KRAS G12C MT colorectal cancer models, SW1463 and ... | [
"CLM:ee44c9fcc3a96a15a8ad27e7",
"CLM:55e0765cb3287e53f9c24e73"
] | [
"PMCID:PMC9808374"
] | [
"SPAN:9bb9deac8bce41bf9dd0eaab"
] | [] | [] | {"qa_id":"QA:e58f1aadcdb8b97a0e237518","qa_group_id":"QAG:3e76481e8cf36a8c39311068","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"The SW1463 model was resistant to single-agent navitoclax treatmen... |
QA:e5f891b70472ef99a7189f9f | QAG:81b20c49627d34ae7532a0df | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Methods A cohort of 190 Jordanian metastatic colorectal cancer patients were enrolled in the trial"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3b483c37ab3f500e48f18ce4","quotes":["Methods A cohort of 190 Jordanian metastatic colorectal cancer patients were... | [
"CLM:3b483c37ab3f500e48f18ce4",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC6934288"
] | [
"SPAN:87c7688e95b6c91b39f81d86"
] | [] | [] | {"qa_id":"QA:e5f891b70472ef99a7189f9f","qa_group_id":"QAG:81b20c49627d34ae7532a0df","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Methods A cohort of 190 Jordanian metastatic colorectal cancer pat... |
QA:e624be22f82e295d1727a0fc | QAG:042eaf86f3dede5db6ee9b50 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Methods In this phase 3, multicenter, open-label, randomized trial, we assigned patients with chemorefractory metastatic colorectal cancer with mutated KRAS G12C who had not received previous treatment with a KRAS G12C inhibitor to receive sotorasib at a dose of 960 mg... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:df2b522c6dbc1e758642b40b","quotes":["Methods In this phase 3, multicenter, open-label, randomized trial, we assig... | [
"CLM:df2b522c6dbc1e758642b40b",
"CLM:3cd4082a1fbc3057f3124cf1"
] | [
"PMID:37870968"
] | [
"SPAN:4b707dc1931994ebe301722d"
] | [] | [] | {"qa_id":"QA:e624be22f82e295d1727a0fc","qa_group_id":"QAG:042eaf86f3dede5db6ee9b50","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Methods In this phase 3, multicenter, open-label, randomized trial... |
QA:e81246fe08d3257ddacb4b27 | QAG:f78d1bfa6556ddc861da57ed | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "In women, BMI and clothing-size was not associated with risk of overall colon cancer, nor with the all-wild-type + pMMR or any-mutation/dMMR subgroups (Table 3 )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:367a58e3ccb3bb8b6ac98774","quotes":["In women, BMI and clothing-size were not associated with risk of overall col... | [
"CLM:367a58e3ccb3bb8b6ac98774",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9470639"
] | [
"SPAN:3ab6719fa5c68cee8cdf9f8c"
] | [] | [] | {"qa_id":"QA:e81246fe08d3257ddacb4b27","qa_group_id":"QAG:f78d1bfa6556ddc861da57ed","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"In women, BMI and clothing-size was not associated with risk of ov... |
QA:e8641cbc80c8e04cff51796b | QAG:33da917221d13ade5c4b14d1 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "A total of 16,357 patients with advanced NSCLC (aNSCLC), 10,430 patients with metastatic CRC (mCRC), and 3323 patients with mPDAC were included in the Flatiron Health-Foundation Medicine CGDB with 5938, 3838, and 1398 patients, respectively, meeting eligibility criteri... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:84c9b007307698278375218d","quotes":["A total of 16,357 patients with advanced NSCLC (aNSCLC), 10,430 patients wit... | [
"CLM:84c9b007307698278375218d",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC9734185"
] | [
"SPAN:9f454757d9b2f1c37963a2ac"
] | [] | [] | {"qa_id":"QA:e8641cbc80c8e04cff51796b","qa_group_id":"QAG:33da917221d13ade5c4b14d1","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"A total of 16,357 patients with advanced NSCLC (aNSCLC), 10,430 pa... |
QA:e8a5462404651d0c8e3eaf4b | QAG:3263c648d33d36deab1a3e74 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "The growth suppression activity of MIR143#12 was higher in colorectal cancer cells than in pancreatic cancer cells, which may reflect the decreases promoted in expression levels of MIR143"? Return the original wording with paper, Claim, and Evidence Span references.
I... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:148bc081246d3469805e8611","quotes":["The growth suppression activity of MIR143#12 was higher in colorectal cancer... | [
"CLM:148bc081246d3469805e8611",
"CLM:55e0765cb3287e53f9c24e73"
] | [
"PMCID:PMC9507988"
] | [
"SPAN:0bf26eaa0b8e92a6a5ce1bd0"
] | [] | [] | {"qa_id":"QA:e8a5462404651d0c8e3eaf4b","qa_group_id":"QAG:3263c648d33d36deab1a3e74","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"The growth suppression activity of MIR143#12 was higher in colorec... |
QA:ec5f74f55fd353239c755a2b | QAG:460a73d1ae2fce4ae3d62ce2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Our work reveals that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant CRC cells and that cetuximab enhances RSL3 promoted ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK"? Return the original wording with paper, Claim, and... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:77c7b41e7940692901dfa7c2","quotes":["Our work reveals that cetuximab enhances the cytotoxic effect of RSL3 on KRA... | [
"CLM:77c7b41e7940692901dfa7c2",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:e3c463163ebc1d811f78928e"
] | [] | [] | {"qa_id":"QA:ec5f74f55fd353239c755a2b","qa_group_id":"QAG:460a73d1ae2fce4ae3d62ce2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Our work reveals that cetuximab enhances the cytotoxic effect of R... |
QA:ef740d0fa8bf759c54b8d2ae | QAG:d0e39609a9f9ccb86aab9058 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Interestingly, we found that cetuximab promoted RSL3 promoted ferroptosis in KRAS mutant CRC cells"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim,... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:ea22b274b1c0546ca6422ac5","quotes":["Interestingly, we found that cetuximab promoted RSL3-induced ferroptosis in ... | [
"CLM:ea22b274b1c0546ca6422ac5",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC8590697"
] | [
"SPAN:39ae57a66bdba5a3f399e66e"
] | [] | [] | {"qa_id":"QA:ef740d0fa8bf759c54b8d2ae","qa_group_id":"QAG:d0e39609a9f9ccb86aab9058","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Interestingly, we found that cetuximab promoted RSL3 promoted ferr... |
QA:f111668852fcce51ace965f3 | QAG:01881841d49c173962f00edd | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "It is shown that GSK-3β inhibition led to apoptosis via p53 activation in p53-wt HCT116 colon cancer cells ( Tan et al., 2005 ) and a RT4 bladder cancer cell line ( Kuroki et al., 2019 )"? Return the original wording with paper, Claim, and Evidence Span references.
In... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fd2e5e305f5e31cdf9879e6b","quotes":["It is shown that GSK-3β inhibition leads to apoptosis via p53 activation in ... | [
"CLM:fd2e5e305f5e31cdf9879e6b",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8696016"
] | [
"SPAN:08391c3b132201f95a304fb8"
] | [] | [] | {"qa_id":"QA:f111668852fcce51ace965f3","qa_group_id":"QAG:01881841d49c173962f00edd","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"It is shown that GSK-3β inhibition led to apoptosis via p53 activa... |
QA:f16244484827f666a47758fd | QAG:c1f8ac4ec7dcbd77ec3e8026 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Nonetheless, the number of somatic variants was associated with ctDNA fraction and residual tumor size in colorectal cancer, but not in lung cancer ( Supplementary Figure S1A )"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated p... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:fc4d0ac05d5ba0b7a7aeca30","quotes":["Nonetheless, the number of somatic variants was associated with ctDNA fracti... | [
"CLM:fc4d0ac05d5ba0b7a7aeca30",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC8987589"
] | [
"SPAN:3dc0be75c38b2d2eb047ff7a"
] | [] | [] | {"qa_id":"QA:f16244484827f666a47758fd","qa_group_id":"QAG:c1f8ac4ec7dcbd77ec3e8026","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Nonetheless, the number of somatic variants was associated with ct... |
QA:f2b20e14be4d04191e1c2d3f | QAG:8822cba3baacfed2f6a46cd7 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "9% 11 , while the combination of divarasib and cetuximab achieved a response rate of 62.5%"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Claim, and Evi... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:513308b69f0351967d37a6ff","quotes":["In patients with CRC who had not received prior KRA... | [
"CLM:513308b69f0351967d37a6ff",
"CLM:1cba67a12cdd2f006af7d9e3",
"CLM:4518a86909c95d8aecd48d25"
] | [
"PMCID:PMC10803265",
"PMCID:PMC10721872"
] | [
"SPAN:e9fcda7b9b8748b3e2289d20",
"SPAN:f88dececbb1113617100b1b9"
] | [
"ASC2:cc59101483bb417d0fbfd9f0"
] | [
"HYP:DCH:2059943c4431fc38266ece42"
] | {"qa_id":"QA:f2b20e14be4d04191e1c2d3f","qa_group_id":"QAG:8822cba3baacfed2f6a46cd7","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"9% 11 , while the combination of divarasib and cetuximab achieved ... |
QA:f5327d7c271827e24848942d | QAG:ff0dede1784fffe5453567d4 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Evolocumab, R-IMPP, and PF-0644846 inhibited the growth of APC/KRAS-mutant CRC cells and CRC organoids"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance requirements: return the exact supporting passage with paper, Cl... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:856e0779732016c149397679","quotes":["Evolocumab, R-IMPP, and PF-0644846 inhibited the growth of APC/KRAS-mutant C... | [
"CLM:856e0779732016c149397679",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:65d5e710b3e1e830ac004c70"
] | [] | [] | {"qa_id":"QA:f5327d7c271827e24848942d","qa_group_id":"QAG:ff0dede1784fffe5453567d4","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Evolocumab, R-IMPP, and PF-0644846 inhibited the growth of APC/KRA... |
QA:f5cc49897c82645f57d43d91 | QAG:070e4e00a2a6fd4021438cba | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Using CRC patient cohorts, isogenic cell lines and transgenic mice, we identify that de novo cholesterol biosynthesis is promoted in APC / KRAS mutant CRC, accompanied by increased geranylgeranyl diphosphate (GGPP)─a metabolite necessary for KRAS activation"? Return th... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:3ebea92eeb68d403668914ce","quotes":["Using CRC patient cohorts, isogenic cell lines and transgenic mice, we ident... | [
"CLM:3ebea92eeb68d403668914ce",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:a273579b2a12a047a815c1f6"
] | [] | [] | {"qa_id":"QA:f5cc49897c82645f57d43d91","qa_group_id":"QAG:070e4e00a2a6fd4021438cba","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Using CRC patient cohorts, isogenic cell lines and transgenic mice... |
QA:f626010e553807f63aff3c1f | QAG:e1374f27b8b6fa85d3fd88b2 | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Taken together, high RyR2 expression in primary CRC tissue was correlated with serosa invasion and vascular tumor thrombus formation, and predicted a poor prognosis"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated provenance re... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:c8f69b14aae51aacef805079","quotes":["Taken together, high RyR2 expression in primary CRC tissue was correlated wi... | [
"CLM:c8f69b14aae51aacef805079",
"CLM:125bd56675f6596398baa1a9"
] | [
"PMCID:PMC10061290"
] | [
"SPAN:72c095886123f9d978489506"
] | [] | [] | {"qa_id":"QA:f626010e553807f63aff3c1f","qa_group_id":"QAG:e1374f27b8b6fa85d3fd88b2","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Taken together, high RyR2 expression in primary CRC tissue was cor... |
QA:f77d4d7ea9efd08e234ef126 | QAG:da658f0c2ca8be2f34ddf08c | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "KRAS G12C MT colorectal cancer cell lines received 1 μmol/L AZ’1569 for the indicated times, and protein lysates were used for WB analysis for the KRAS downstream effectors"? Return the original wording with paper, Claim, and Evidence Span references.
Integrated prove... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification","cross_paper_provenance"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:1cea4336fb1737a7b0a9361a","quotes":["KRAS G12C MT colorectal cancer cell lines were trea... | [
"CLM:1cea4336fb1737a7b0a9361a",
"CLM:1cba67a12cdd2f006af7d9e3",
"CLM:78af6bf902ed1d5cd6e7c0da"
] | [
"PMCID:PMC9808374",
"PMCID:PMC9255981"
] | [
"SPAN:fd9bebdd68e348d642134f6b",
"SPAN:82af22e452fed4997190df8b",
"SPAN:9c20e32d1bc68df87e8fbe43"
] | [
"ASC2:996fcbadc6abdd17896c8cc2"
] | [
"HYP:DCH:c06a083a844ece16d3a43a54"
] | {"qa_id":"QA:f77d4d7ea9efd08e234ef126","qa_group_id":"QAG:da658f0c2ca8be2f34ddf08c","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"KRAS G12C MT colorectal cancer cell lines received 1 μmol/L AZ’156... |
QA:f7c543c8fb1e9c6703c03c10 | QAG:0dd454259fbd5b25e281ac5e | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "To address this question, we applied mass spectrometry-based proteomics and studied underlying CET resistance in CRC cell lines displaying CET resistance promoted by activating KRAS alterations with a special focus on kinome reprogramming"? Return the original wording ... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:0830364446075284afe2e09f","quotes":["To address this question, we applied mass spectrometry-based proteomics and ... | [
"CLM:0830364446075284afe2e09f",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9931833"
] | [
"SPAN:b12516004b3bad48f62f5191"
] | [] | [] | {"qa_id":"QA:f7c543c8fb1e9c6703c03c10","qa_group_id":"QAG:0dd454259fbd5b25e281ac5e","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"To address this question, we applied mass spectrometry-based prote... |
QA:f84debfbbf25ad8da24d0a7f | QAG:7fac78d215a6b1b3d174f4cb | provenance_qa | exact_evidence_retrieval | provenance_qa | G009 | en | train | Which exact source passage supports the statement "Using CRC patient cohorts, isogenic cell lines and transgenic mice, we identify that de novo cholesterol biosynthesis is induced in APC / KRAS mutant CRC, accompanied by increased geranylgeranyl diphosphate (GGPP)─a metabolite necessary for KRAS activation"? Return the... | {"answer_type":"integrated_provenance","embedded_answer_types":["exact_evidence_retrieval","claim_evidence_verification"],"exact_evidence_retrieval":{"answer_type":"exact_evidence_retrieval","claim_id":"CLM:89a895554e5576c8ae150b61","quotes":["Using CRC patient cohorts, isogenic cell lines and transgenic mice, we ident... | [
"CLM:89a895554e5576c8ae150b61",
"CLM:1cba67a12cdd2f006af7d9e3"
] | [
"PMCID:PMC9270407"
] | [
"SPAN:a273579b2a12a047a815c1f6"
] | [] | [] | {"qa_id":"QA:f84debfbbf25ad8da24d0a7f","qa_group_id":"QAG:7fac78d215a6b1b3d174f4cb","qa_family":"provenance_qa","subtask_type":"exact_evidence_retrieval","language":"en","cluster_id":"G009","question":"Which exact source passage supports the statement \"Using CRC patient cohorts, isogenic cell lines and transgenic mice... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.